Wednesday, October 16
2.0 CME CREDITS
This course will focus on the current rationale for subtyping nonsmall cell lung cancer (NSCLC) and the appropriate use of immunohistochemistry (IHC). It will clarify what role histology plays in molecular testing and the use of new therapeutic agents. Faculty will explain the latest understanding of acquired resistance to therapy and demonstrate the appropriate use of FNA in rebiopsying patients with known histology for the further delineation of therapy.
You will learn to:
Maureen F. Zakowski, MD, FCAP
This course will be streamed live during CAP ’13. Learn more about how to participate. Please note that CME will not be offered for viewing a session via live streaming.